Molecular Partners AG (MOLN) shareholders
Close on Nov 12, 2026Market cap $121.53MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BVF Partners L.P. Joint filing with BVF Inc. (24.50%), Mark N. Lampert (24.50%) and 3 more | 9,888,592 | 24.50% | 13D (active) amendment | Oct 25, 2024 |
| Suvretta Capital Management, LLC Joint filing with Averill Master Fund, Ltd. (10.60%), Aaron Cowen (10.60%) | 4,284,806 | 10.60% | 13G (passive) | Jun 15, 2021 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,144,607 | 5.80% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MOLN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2,221,494 | 5.50% | $8.60M | – | 0.16% |
| Bvf Inc/Il | 1,353,968 | 3.35% | $5.15M | – | 0.13% |
| Citadel Advisors LLC | 17,179 | 0.04% | $65.28K | New | 0.00% |
| Morgan Stanley | 367 | 0.00% | $1.42K | – | 0.00% |
| UBS Group AG | 279 | 0.00% | $1.08K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 5 | 4M | 8.9% | 2 / 0 | 0 / 1 | 0M | 0M |
| Q1 2026 | 4 | 4M | 8.9% | 0 / 1 | 0 / 2 | 0M | 0M |
| Q4 2025 | 6 | 4M | 8.9% | 1 / 0 | 2 / 1 | 0M | 0M |
| Q3 2025 | 6 | 4M | 8.9% | 0 / 1 | 1 / 0 | 0M | 0M |
| Q2 2025 | 6 | 4M | 8.9% | 1 / 1 | 0 / 1 | 0M | 0M |
| Q1 2025 | 6 | 4M | 8.9% | 1 / 0 | 1 / 0 | 0M | 0M |
| Q4 2024 | 5 | 4M | 8.9% | 0 / 3 | 1 / 0 | 3M | 0M |
| Q3 2024 | 5 | 1M | 2.1% | 0 / 2 | 0 / 3 | 0M | 0M |
| Q2 2024 | 8 | 1M | 2.1% | 1 / 1 | 2 / 1 | 0M | 0M |
| Q1 2024 | 8 | 1M | 2.3% | 2 / 1 | 0 / 2 | 0M | 0M |
| Q4 2023 | 8 | 1M | 2.4% | 1 / 1 | 1 / 0 | 0M | 0M |
| Q3 2023 | 7 | 1M | 2.4% | 1 / 1 | 1 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
1 funds held MOLN in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MOLN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | 1,070 | 0.00% | $4.45K | 0.00% | May 31, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Molecular Partners's stock actually held short. Settlement fails (shares not delivered on time) peaked at 655 shares on Aug 26, 2026 over the last 90 days.
See a number that looks wrong?